Home : DrugWatch : Mylotarg : Wikipedia : Gemtuzumab ozogamicin

Wikipedia - Gemtuzumab ozogamicin

Gemtuzumab ozogamicin ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD33
Identifiers
CAS number 220578-59-6
ATC code L01XC05
DrugBank DB00056
Chemical data
Formula  ?
Mol. mass 151–153 kDa
Therapeutic considerations
Pregnancy cat. D
Legal status ?-only (US)
Routes Intravenous

Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukemia.

It is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML) who are not considered candidates for standard chemotherapy.[1]

A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in the absence of bone marrow transplantation.[2] The onset of VOD can also be delayed and can occur at increased frequency following bone marrow transplantation.[3]

Common side effects of administration include shivering, fever, nausea and vomiting. Serious side effects include severe myelosuppression (suppressed activity of bone marrow, which is involved in formation of various blood cells [found in 98% of patients]), disorder of the respiratory system, tumor lysis syndrome, and Type III hypersensitivity.

[edit] See also

[edit] References

  1. ^ Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001). "Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.". Clin Cancer Res 7 (6): 1490–6. PMID 11410481. 
  2. ^ Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH (2001). "Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.". Cancer 92 (2): 406–13. doi:10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U. PMID 11466696. 
  3. ^ Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ (2003). "Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.". Blood 102 (5): 1578–82. doi:10.1182/blood-2003-01-0255. PMID 12738663. 
v • d • e
Targeted therapy / extracellular chemotherapeutic agents/antineoplastic agents (L01)
CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine kinase inhibitors ("-nib")
Other
v • d • e
Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)
"-lizu-" (immune system)
"-bazu-" (bacterial)
"-cizu-" (cardiovascular)
"-nezu-"/"-neuzu-" (nervous system)
"-toxazu-" (toxin as target)
"-vizu-" (viral)
"-kizu-" (interleukin as target)
"-anibizu-" (angiogenesis inhibitor)
†Undergoing clinical trials. §Never marketed.


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin"

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Gemtuzumab ozogamicin".

Need A Mylotarg Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Want to contact a District of Columbia Mylotarg attorney? ...Get a free case evaluation from one of our District of Columbia Mylotarg attorneys now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Mylotarg Case - Submit Your Information Below

Do you need legal assistance with your Mylotarg case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Mylotarg Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.